The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II study of abemaciclib, a CDK4/6 inhibitor, in participants with HIV-associated and HIV-negative Kaposi sarcoma.
 
Ramya Ramaswami
Research Funding - Celgene (Inst); CTI BioPharma Corp (Inst); EMD Serono (Inst); Genentech (Inst); Merck Serono (Inst)
 
Jose Mercado-Matos
No Relationships to Disclose
 
Kathryn Lurain
Research Funding - Bristol-Myers Squibb/Celgene (Inst); CTI BioPharma Corp (Inst); EMD Serono (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Miltenyi Biotec (Inst)
 
Anaida Widell
No Relationships to Disclose
 
Irene Ekwede
No Relationships to Disclose
 
Ijeoma Agwu
No Relationships to Disclose
 
Margaret Namubiru
No Relationships to Disclose
 
Thomas Odeny
Research Funding - Gilead Sciences
 
Crystal Lu
No Relationships to Disclose
 
Denise Whitby
No Relationships to Disclose
 
Robert Yarchoan
Research Funding - Bristol-Myers Squibb/Celgene (Inst); CTI BioPharma Corp (Inst); EMD Serono (Inst); Janssen Research & Development (Inst); Lentigen Technology (Inst); Lilly (Inst); Merck (Inst); PDS Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - Patent related to increase in immune surface markers by pomalidomide, lenalidomide and related drugs in patients with KSHV-associated diseases (Inst); Patent(s) on the treatment of HIV and hepatitis virus with an antiviral drug and a vaccine to prevent resistance (Inst); Patents on the treatment of Kaposi sarcoma with IL-12 (Inst); Various patents including patents on anti-HIV therapies and soluble IL-2 receptor; mostly expired. (Inst); Various patents on vasostatin, KSHV vIL-6, internalization of surface markers, calreticulin, and calreticulin fragments (Inst)